Home»News & Opinion»Margetuximab approved with chemotherapy to treat metastatic, HER2-positive breast cancer after progression on other targeted therapies
News & Opinion
Margetuximab approved with chemotherapy to treat metastatic, HER2-positive breast cancer after progression on other targeted therapies
Approval based on phase III SOPHIA trial, but advocates question how much it adds to treatment